

HR 3777

Drug Price Competition Act of 2009

Congress: 111 (2009–2011, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 8, 2009

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 9, 2009)

Official Text: https://www.congress.gov/bill/111th-congress/house-bill/3777

Sponsor

Name: Rep. Hastings, Alcee L. [D-FL-23]

Party: Democratic • State: FL • Chamber: House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Taylor, Gene [D-MS-4]	D · MS		Oct 8, 2009
Rep. Slaughter, Louise McIntosh [D-NY-28]	D · NY		Feb 2, 2010

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 9, 2009

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
111 S 1315	Identical bill	Jun 22, 2009: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Oct 8, 2009)

Drug Price Competition Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act to expand the definition of "first applicant" under such Act to allow a generic drug manufacturer that is currently considered an applicant subsequent to a brand-name manufacturer's 180-day exclusivity period to qualify as a first applicant for purposes of filing an abbreviated application for a new drug. Requires such applicant to submit a substantially complete application that contains and lawfully maintains a certification for such drug.

Actions Timeline

- **Oct 9, 2009:** Referred to the Subcommittee on Health.
- **Oct 8, 2009:** Introduced in House
- **Oct 8, 2009:** Sponsor introductory remarks on measure. (CR E2487-2488)
- **Oct 8, 2009:** Referred to the House Committee on Energy and Commerce.